Immunolymphscintigraphy with BCD-F9 Monoclonal Antibody and Its F(ab’)2 Fragments for the Preoperative Staging of Breast Cancers

  • Rosemonde Mandeville
  • Christian Schatten
  • Norbert Pateisky
  • Marie-Josée Dicaire
  • Benoît Barbeau
  • Brigitte Grouix

Abstract

In breast cancer, assessment of axillary lymph node status is the most important prognostic factor for accurate staging, management and follow-up of patients with primary tumors. Several studies suggest that preoperative staging with techniques as direct breast lymphography, ultrasound and CT-scan often fail to identify the extent of the metastatic involvement in the axilla. To this end, we have developed a novel, simple, non-invasive and reliable immunolymphscintigraphic(ILS) technique that allows the accurate preoperative diagnosis of lymph node metastasis in patients with early stages of breast cancer1–4. In this article, we report on a consecutive series of thirty-nine breast cancer patients undergoing preoperative staging by ILS using the BCD-F9 monoclonal antibody or its F(ab’)2 fragments. Each patient received 1 mg of a purified preparation containing 1 mCi of Iodine-123, by a subcutaneous injection into the fingerwebs between the 2nd and 3rd finger of both hands. Scans obtained 4, 8 and 12 hours after injection demonstrated adequate tumor accumulation of radiolabeled antibody and accurate tumor visualisation without any background substraction. ILS results were always compared to the histopathological staging. When intact immunoglobulin molecules were injected, 10 out of 11 patients with breast cancer were true positives and 19 out of 21 were true negatives. For the F(ab’)2 fragments, ILS results were positive in 3 out of 3 patients with metastatic cancer and negative in 3 out of 4 patients without metastatic involvement of the axilla. Most importantly to our study, all of the 12 patients with benign breast disease studied showed no positive imaging.

Keywords

True Negative Preoperative Staging Benign Breast Disease Axillary Lymph Node Metastasis Axillary Lymph Node Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. Mandeville, N. Pateisky, K. Philipp, E. Kubista, F. Dumas and B. Grouix, Immunoscintigraphy of axillary lymph node metastasis in breast cancer patients using monoclonal antibodies: First clinical findings, Anticancer Research 6: 1257(1986).PubMedGoogle Scholar
  2. 2.
    N. Pateisky, C. Schatten, H. Enzelsberger, J. Burchell and R. Mandeville, Immunlymphszintigraphie: Ein neues Verfahren fűr nicht-invasives Lymphknoten-Staging, dargestellt am Beispiel des Mammakarzinoms, Dtsch. Med. Wschr., 113: 250(1987).CrossRefGoogle Scholar
  3. 3.
    C. Schatten, N. Pateisky, H. Enzelsberger, B. Grouix and R. Mandeville, Clinical value of immunolymphscintigraphy in patients with breast cancer, In Vivo, in press(1988).Google Scholar
  4. 4.
    R. Mandeville, N. Pateisky, C. Schatten, A. Amarouch, M. Zelechowska, S. Sidrac-Ghali, L. Giroux and B. Grouix, Axillary lymphscintigraphy with 123-I-labeled monoclonal antibody for the preoperative detection of lymph node metastasis in breast cancer patients, in “Monoclonal Antibodies in Clinical Oncology”, J.Y. Douillard and R.A. Carrano, eds., Marcel Deckker Publisher, N.Y., in press(1989).Google Scholar
  5. 5.
    D. Pressman and G. Keighley, The zone of activity of antibodies as determined by the use of radioactive tracers. The zone of activity of nephrotoxic antikidney serum, J.Immunol. 59: 141(1948).PubMedGoogle Scholar
  6. 6.
    J.-P. Mach, F. Buchegger, M. Forni, J. Ritschard, C. Berche, J.-D. Lumbroso, M. Schreyer, C. Girardet, R. S. Accolla and S. Carrel, Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human carcinoma by external photoscanning and tomoscintigraphy, Immunol. Today 2: 239(1981).CrossRefGoogle Scholar
  7. 7.
    T. Ghose, S. T. Norwell, J. Aquino, P. Belitsky, J. Tai, A. Guclu and A.H. Blair, Localization of 131-I-labeled antibodies in human renal cell carcinomas and in a mouse hepatoma and correlation with tumor detection by photoscanning, Cancer Res. 40: 3018(1980).PubMedGoogle Scholar
  8. 8.
    S.M. Larson, J.P. Brown, P.W. Wright, J.A. Carrasquillo, I. Hellstrőm, K.-E. Hellstrőm, Imaging of melanoma with I-131-labeled monoclonal antibodies, J. Nuclear Med. 24: 123(1983).Google Scholar
  9. 9.
    H.M. Smedley, P. Finan, E. S. Lennox, A. Ritson, F. Takei, P. Wraight and K. Sikora, Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody, Br. J.Cancer 47: 253(1983).CrossRefGoogle Scholar
  10. 10.
    J. Bubenik, J. Kieler, P. Perlmann, S. Paulie, H. Koho, et al., Monoclonal antibody against human urinary bladder carcinomas. Selectivity and utilization for gamma scintigraphy, Eur. J.Cancer Clin. Oncol. 21: 701(1985).CrossRefGoogle Scholar
  11. 11.
    A.H. Zimmer, S.T. Rosen, S.M. Spies, M.R. Palovina, J.D. Minna, W.C. Spies and E.A. Silverstein, Radioimmunoimaging of human small cell lung carcinomas with I-131 tumor specific monoclonal antibody, Hybridoma 4: 1(1985).PubMedCrossRefGoogle Scholar
  12. 12.
    P.A. Bunn, J.A. Carrasquillo, A.M. Keeman, et. al., Imaging of T-cell lymphoma by radiolabelled monoclonal antibodies, Lancet ii: 1219(1984).CrossRefGoogle Scholar
  13. 13.
    R. Mandeville, J. Lecomte, F.-M. Sombo, J.P. Chausseau and L. Giroux, Production, purification and biochemical characterization of monoclonal antibodies reacting with breast carcinoma cells, in “Monoclonal Antibodies: Diagnostic and Therapeutic Applications in Tumor and Transplantation”, S. N. Chaterjee, ed., PBS Publishing Compagny Inc., Littleton, Mass.(1985): 63.Google Scholar
  14. 14.
    R. Mandeville, L. Giroux, J. Lecomte, J.-P. Chausseau, F. Dumas, I. Ajdukovic, D. Vidal and F. Boury, Production and characterization of monoclonal antibodies showing a different spectrum of reactivity to human breast tissue, Cancer Detection and Prevention 10:89(1987).Google Scholar
  15. 15.
    D.F. Hayes, M.R. Zalutsky, W. Kaplan, M. Noska, A. Thor, D. Colcher and D.W. Kufe, Pharmacokinetics of radiolabeled monoclonal antibody B6. 2 in patients with metastatic cancer, Cancer Res. 46: 3157(1986).PubMedGoogle Scholar
  16. 16.
    N. Pateisky, K. Philipp, W.D. Skodler, K. Czerwenka, G. Hamilton and J. Burchell, Radioimmunodetection in patients with suspected ovarian cancer, J.Nucl. Med. 26: 1369(1985).PubMedGoogle Scholar
  17. 17.
    G.L. Buraggi, L. Callegaro, A. Turrin, N. Cascinelli, et al., Immunoscintigraphy with 123I, 99mTc and 111In-labelled F(ab ’)2 fragments of monoclonal antibodies to a human high molecular weightmelanoma associated antigen, J.Nucl Med.. 28: 283(1984).Google Scholar
  18. 18.
    B. Delaloye, A. Bischof-Delaloye, F. Buchegger, V. vonFliedner, J.-P. Grob, J.-C. Volant, J. Pettavel and J.-P. Mach, Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab ’)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies, J.Clin. Invest. 77: 301(1986).PubMedCrossRefGoogle Scholar
  19. 19.
    A.A. Epenetos, D. Snook, H. Durbin, P.M. Johnson and J. Taylor Papadimitriou, Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms, Cancer Res. 46: 3183(1986).PubMedGoogle Scholar
  20. 20.
    S. M. Larson, J.A. Carrasquillo, K.A. Krohn, R.W. Mc Guffin, D.L. Williams, I. Hellstrőm, K.-E. Hellstrőm and D. Lyster, Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies, JAMA 249:811(1983).PubMedCrossRefGoogle Scholar
  21. 21.
    S. M. Larson, J.A. Carrasquillo and J.C. Reynolds, Radioimmunodetection and radioimmunotherapy, Cancer Invest. 2(5): 363(1984).PubMedCrossRefGoogle Scholar
  22. 22.
    F. Buchegger, C.M. Haskell, M. Schreyer, B.R. Scazziga, R. Randin, S. Carrel and J.-P. Mach, Radiolabeled fragments of monoclonal anti-CEA antibodies for localization of human colon carcinoma grafted into nude mice. J.Exp Med. 158:413(1983).PubMedCrossRefGoogle Scholar
  23. 23.
    S.E. Halpern, F. Buchegger, H. Schreyer and J.-P. Mach, Effect of size of radiolabeled antibody and fragments on tumor uptake and distribution in nephrectomized mice, J.Nucl. Med. 25 :p112(1984).Google Scholar
  24. 24.
    J.N. Weinstein, M.A. Steller, A.M. Keeman, D.G. Covell, M.E. Key, S. M. Sieber, R.K. Oldham, K.M. Hwang and R.J. Parker, Monoclonal antibodies in the lymphatics: Selective delivery to lymph node metastases of a solid tumor, Science 222 :423(1983).PubMedCrossRefGoogle Scholar
  25. 25.
    M.A. Steller, R. J. Parker, D.G. Covell, O.D. Holton III, A.M. Keeman, S.M. Sieber and J.N. Weinstein, Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence, Cancer Res. 46: 1830(1986).PubMedGoogle Scholar
  26. 26.
    S. M. Larson, Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy, J.Nucl. Med. 26: 538(1985).PubMedGoogle Scholar
  27. 27.
    T. Bayes, An essay toward solving a problem in the doctrine of chance, Philos. Trans. R. Soc. London 53: 370(1763).CrossRefGoogle Scholar
  28. 28.
    P. Leclerc and P. Douville, Probabilité et théorème de Bayes, Ann.Biochim. Clin. Qué. 24(4): 149p(1985).Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Rosemonde Mandeville
    • 1
    • 2
  • Christian Schatten
    • 1
    • 2
  • Norbert Pateisky
    • 1
    • 2
  • Marie-Josée Dicaire
    • 1
    • 2
  • Benoît Barbeau
    • 1
    • 2
  • Brigitte Grouix
    • 1
    • 2
  1. 1.Institut Armand-FrappierImmunology Research CenterLaval-des-RapidesCanada
  2. 2.First Department of Obstetrics and GynecologyUniversity of ViennaViennaAustria

Personalised recommendations